Background: Clozapine remains the antipsychotic of choice for refractory schizophrenia. Given the particular side effects of clozapine including neutropenia and myelosuppression, safety and efficacy of add-on chemotherapy for patients who are already under clozapine treatment remain unknown. Objective: We present evidence from a patient with a diagnosis of refractory schizophrenia on clozapine medication, who required essential chemotherapy for chronic lymphocytic leukemia (CLL). We have also reviewed literature regarding this challenging clinical dilemma.
Introduction
Clozapine remains the most efficacious and in most cases a life-saving antipsychotic in patients with refractory schizophrenia [Munshi et al. 2013] . Unfortunately, agranulocytosis (revealed by a decline in peripheral neutrophil granulocytes below the level of 0.5 × 10 9 /l) is a rare but potentially fatal adverse drug reaction. At least 0.8% [Pirmohamed and Park, 1997 ] of patients treated with clozapine develop agranulocytosis. There are no clinical or other parameters to predict this adverse reaction in a given patient and over 80% of the cases occur within the first 18 weeks of treatment [Munro et al. 1999] . Precise pathophysiological origins of agranulocytosis remain unclear.
Such patients who develop malignancy and require life-saving chemotherapy frequently develop myelosuppression and neutropenia. Therefore, we are presenting a case in which a patient was given diagnosis of schizophrenia (refractory) and required chemotherapy for chronic lymphocytic leukemia (CLL). In addition, we have reviewed and discussed evidence regarding patients presenting such clinical therapeutic challenge. A summary of the literature review is given in Table 1 . 
Yes
With the concern of agranulocytosis clozapine was stopped. After two cycles of chemotherapy, clozapine restarted due to decompensation. With concern that the clozapine might have been responsible for neutropenia, we replaced clozapine treatment with 8 mg/day of risperidone. As soon as clozapine treatment discontinued, the patient became agitated with delusions and hallucinations. With the consent of his wife and support by the hematological team, clozapine was reintroduced and titrated to the previous dose. In addition, he was given granulocyte-colony stimulating factor (G-CSF) injection twice to stimulate the reproduction of white blood cells. His mental status improved rapidly and he has been stable since then. He was able to complete two other cycles of FCR chemotherapy with no further incident of neutropenia. CLL was remitted and the patient was mentally stable in the most recent follow up, about a year after chemotherapy was completed, under clozapine treatment.
Wesson

Review of evidence
To make a decision whether to stop or to carry on with clozapine during cancer chemotherapy is a rather difficult case. For several reasons it is hard to terminate or to interrupt clozapine treatment. Abrupt cessation of clozapine may cause serious problems such as rapid deterioration of mental status, relapse of psychotic symptoms and/or delayed response to other psychotic drugs [Frieri et al. 2008] which could disrupt patients' adherence to chemotherapy. Therefore, proper liaison between hematology and psychiatry team should be established when dealing with such patients.
Determining the causes of neutropenia, whether associated with clozapine or a chemotherapeutic agent, is not always easy. The temporal relationship between the onset of neutropenia and initiation of cancer chemotherapy may guide physicians. Depending on the type or dose of chemotherapy, neutrophil counts generally start to drop about a week after each cycle of chemotherapy and usually drop to the lowest level about 7-14 days after treatment. This period is called nadir, the drop in neutrophil counts at the nadir of chemotherapy should not lead clinicians to stop clozapine. The risk of clozapine-induced agranulocytosis reduces substantially after the first 6 months of its use [Munshi et al. 2013] . Other risk factors defined are older age (often over 50 years of age) and those peculiar to the Asian race [Munro et al. 1999] . The risk of clozapine-induced agranulocytosis is not dose related.
Although there is no consensus about the mechanism of clozapine-induced agranulocytosis, it seems it can be best explained by genetic and immunotoxic factors [Guzelcan and Scholte, 2006 ]. Of the genetic basis of this adverse effect, there are some studies suggesting that specific human leukocyte antigen (HLA) subtypes are related to patients' susceptibility to develop clozapine-induced agranulocytosis [Lieberman et al. 1990; Dettling et al. 2001 ]. These findings emphasize that this adverse effect is an idiosyncratic drug reaction [Uetrecht, 1989] , which contrasts with the predictable course of chemotherapyinduced myelosuppression. No information is reported for direct toxic effect of clozapine on neutrophils. Yet there is some evidence about binding reactive metabolites might disrupt the neutrophil function or this may lead to the haptenization and cause immunity-mediated destruction [Pirmohamed and Park, 1997] . It has been shown that clozapine could activate common apoptotic pathways shared with chemotherapeutic drugs [Fehsel et al. 2005 ], but no evidence suggests a synergistic effect of concomitant use on neutrophil counts. These theories about the mechanisms of clozapine-induced agranulocytosis are to be separated from those of antineoplastic drugs and this difference leads us to the idea that continuing clozapine in the course of chemotherapy may be relatively a safe treatment method for patients already stabilized on clozapine.
Whatever the cause of agranulocytosis, clozapine or chemotherapy, G-CSFs may be useful to replenish white cell counts. G-CSFs have been given in the treatment of clozapine-induced agranulocytosis [Sperner-Unterweger et al. 1998; Hagg et al. 2003 ]. Furthermore, clinicians have reported successful use of G-CSFs despite severe neutropenia in order to hold clozapine treatment [Sperner-Unterweger et al. 1998; Conus et al. 2001; Hagg et al. 2003 ]. Yet one should not underestimate the dangers of this combination, as the absolute neutrophil counts may continue to drop despite starting G-CSFs [Majczenko and Stewart, 2008] . There have been few reports concerning the use of G-CSFs in conjunction with clozapine and cancer chemotherapy [Kolli et al. 2013; Sankaranarayanan et al. 2013] . In our patient we also found the use of G-CSFs beneficial. However, guidelines limit the use of G-CSFs in the course of cancer chemotherapy according to the risk of febrile neutropenia, considering the cost of this treatment [Aapro et al. 2010] . In our case the oncology team decided to give G-CSFs which probably reduced the severity and duration of chemotherapy-induced neutropenia.
Conclusion
Current data are insufficient to guide clinicians about the combined use of clozapine and chemotherapy and it seems difficult to expand it with controlled randomized studies. A general conclusion drawn from the reported cases is that a combination of clozapine use and chemotherapeutic agents does not cause additional hematological worsening. Our case also supports the safe use of clozapine during chemotherapy.
Patients stabilized on clozapine are generally treatment resistant and discontinuing clozapine is often followed by the emergence of more symptoms, the consequences of discontinuing clozapine may even be more disastrous such as rapid deterioration of mental status and refusing chemotherapy in these very difficult patients generally resistant to multiple combination of antipsychotics. Therefore, clinicians should not discontinue clozapine during chemotherapy unless certain predictors such as the occurrence of neutropenia many weeks after completion of chemotherapy, indicate strongly that clozapine, rather than the chemotherapy, may be the likely the cause of neutropenia. For the management of such patients a multidisciplinary approach, especially a proper liaison between hematology and psychiatry teams, should be established, and patients should be monitored closely.
